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The sweet spot for biologics: recent advances in characterization of biotherapeutic
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ABSTRACT
Introduction: Glycosylation is recognized as a Critical Quality Attribute for therapeutic glycoproteins
such as monoclonal antibodies, fusion proteins and therapeutic replacement enzymes. Hence, efficient
and quantitative glycan analysis techniques have been increasingly important for their discovery,
development and quality control. The aim of this review is to highlight relevant and recent advances
in analytical technologies for characterization of biotherapeutic glycoproteins.
Areas covered: The review gives an overview of the glycosylation trends of biotherapeutics approved
in 2016 and 2017 by FDA. It describes current and novel analytical technologies for characterization of
therapeutic glycoproteins and is explored in the context of released glycan, glycopeptide or intact
glycoprotein analysis. Ultra performance liquid chromatography, mass spectrometry and capillary
electrophoresis technologies are explored in this context.
Expert commentary: There is a need for the biopharmaceutical industry to incorporate novel state of
the art analytical technologies into existing and new therapeutic glycoprotein workflows for safer and
more efficient biotherapeutics and for the improvement of future biotherapeutic design. Additionally, at
present, there is no ‘gold-standard’ approach to address all the regulatory requirements and as such
this will involve the use of orthogonal glycoanalytical technologies with a view to gain diagnostic
information about the therapeutic glycoprotein.
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Glycosylation of biotherapeutic glycoproteins plays an important
role in cellular communication in vivo and can alter function,
safety, and efficacy of the drug. It is estimated that more than
50% of human proteins are glycosylated and approximately 90%
of these contain N-linked glycans or a combination of N-linked
and O-linked glycans [1]. Many of the protein-based biothera-
peutics approved or in clinical trials are glycoproteins, including
the large class of monoclonal antibodies (mAbs), cytokines and
enzyme replacement therapies. mAbs based on immunoglobulin
G 1 (IgG1), an antibody for Fc receptor binding are frequently
exploited as therapeutic agents, see Figure 1. Human IgG1 anti-
bodies contain two conserved N-glycan sites on the Fc (fragment
crystallizable) at Asn 297 on each heavy chain, and up to four
additionalN-glycan sites on the Fab (fragment antibody binding)
[2]. N-glycans contain a common chitobiose core of two
N-acetylglucosamine residues (GlcNAc) linked to an asparagine
residue on the glycoprotein via an amide bond and extended
with a trimannosyl core, see Figure 1. This core structure may be
decorated with additional monosaccharide residues such as
mannose (Man), GlcNAc, galactose (Gal), fucose (Fuc), bisecting
GlcNAc, and sialic acids such as N-acetyl neuraminic acid (NANA)
or N-glycolyl neuraminic acid (NGNA). Biosynthesis of eukaryotic
N- and O-glycosylation has been extensively described in the
literature previously [4,5].
Recombinant cytokines are used in awide variety of infectious
and autoimmune diseases, in immunocompromised patients
with AIDS (acquired immune deficiency syndrome), and in neo-
plasia [6]. Recombinant human interferon-β 1a glycoproteins
such as Avonex and Rebif are widely used as a first-line treatment
for multiple sclerosis (MS) [7]. The native glycoprotein contains a
single N-glycan site and the recombinant versions produced in
Chinese Hamster Ovary (CHO) cells, mouse epithelial cells, and
human lung adenocarcinoma cells all contain themost abundant
native biantennary complex-type N-glycans present in the native
glycoprotein [8]. Recently, glycoengineered variants have been
produced using site-specific hyperglycosylation via site-directed
mutagenesis to improve pharmacokinetic properties of the gly-
coprotein [7]. Therapeutic glycoproteins have also found appli-
cations in enzyme replacement therapies such as agalsidase alfa
(Replagal) and agalsidase beta (Fabrazyme) which have changed
the treatment of Anderson-Fabry disease. The recombinant
enzyme agalsidase alfa is produced in a cultured human cell
line whereas the agalsidase beta is produced in CHO cells, both
glycoproteins contain complex type N-glycans [9,10].
In contrast to N-glycans, O-glycans on therapeutic glycopro-
teins do not contain a common core structure [11]. They are most
commonly attached to serine/threonine residues on protein/pep-
tide structures but can also be attached via hydroxylysine, hydro-
xyproline, or tyrosine residues. Mucin type O-glycans, which do
contain common core structures, are noteworthy and are found
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on mucins as well as many therapeutic glycoproteins, see repre-
sentativeO-glycan structures in Figure 2 [12,13]. The initiation step
in synthesis is the attachment of the first carbohydrate residue,
GalNAc, to selected serine and threonine residues in proteins
using GalNAc-transferases. This transformation is harnessed in
























Figure 1. IgG antibody structures and N-glycan structures. a) Schematic representation of the glycoprotein IgG, a common motif for mAbs. Glycosylation sites are
decorated with N-glycans: two conserved fragment crystallisable (Fc) N-glycan sites linked to asparagine 297 in CH2 domains and four potential fragment antibody
binding (Fab) N-glycan sites linked to the variable regions on the heavy and light chains. Depending on the glycoform, the N-glycans may be attached to the
variable regions of the light chain, the heavy chain or both and asymmetric Fc and Fab N-glycans can also exist [2], although many mAbs contain only Fc
glycosylation. b) All N-glycans contain common core pentasaccharide (Man3GlcNAc2) containing a chitobiose core of two N-acetylglucosamine (GlcNAc) residues
attached to asparagine residue on protein backbone via an amide bond. Three mannose (Man) residues are attached to the outer GlcNAc residue. The Man residues
can be extended with an array of additional glycans such as GlcNAc, galactose and sialic acids. The glycan structures are depicted with SNFG nomenclature [3].





The O-linked glycans are released chemically using








Y N N N N N
Hydrazinolysis Y Y Y U U U
β-elimination N Y Y N N N
Figure 2. Methods of release of N- and O-linked glycans for biotherapeutics shown on erythropoietin (EPO) as a representative example. N- and O-glycan structures
on the glycoprotein are presented in red and orange respectively and can be cleaved at the site of attachment to the protein. N-linked glycans are usually cleaved
enzymatically using PNGase F or PNGase A, whereas O-linked glycans are more commonly cleaved using chemical means, with hydrazinolysis and β-elimination
methods. The O-glycans are attached to the glycoproteins via amino acid residues serine (Ser), threonine (Thr), hydroxyproline (Hyp), tryrosine (Tyr) on the side
chains but can also be located on carboxylic moieties of either serine/threonine. The table inset presents which type of glycans can be cleaved using the specified
methods, Y for yes, N for no and U for uncertain. (Permission for reprint of EPO structure granted by Dr. Mark Wormald, Oxford Glycobiology Institute).
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proteins is employed to enhance pharmacodynamic properties of
the biologic whereby polyethylene glycol is transferred to the
recombinant protein expressed in Escherichia coli (lacking mucin
type O-glycosylation) to specific acceptor sites directed by
GalNAc-transferases [13–15].
By characterization of released N- and O-glycan structures,
glycopeptide, and intact glycoprotein structures in biotherapeu-
tics, we can identify their origin (mammalian, plant, or insect) and
mitigate undesired immunological responses using glycoengi-
neering approaches including systems such as CRISPR-Cas9
[16,17]. This review gives an overview of biotherapeutics recently
approved in 2016 and 2017 with consideration toward suitable
glycoanalytical technologies. It also showcases analytic meth-
odologies for the characterization of therapeutic glycoproteins
with a focus on released N- and O-glycan characterization, gly-
copeptide characterization, and glycoprotein characterization,
see Figure 3. Additional reviews relating to glycoprotein charac-
terization are included [18–21].
2. Glycoprotein biotherapeutics approved by FDA in
2016 and 2017 and considerations for glycoanalytics
Glycosylation is a CQA that must be presented to regulatory
bodies for approval of therapeutic glycoproteins. In the past
decade, the emergence of mAbs has dominated the global
biopharmaceutical market [22]. At the same time, state-of-the-
art glycoanalytical technologies have emerged to provide
detailed process and product information. To gain insight into
the analytical techniques that need further development, we
first need to understand the shape of the current biopharma-
ceutical landscape. This section therefore seeks to showcase the
degree of recently approved biopharmaceuticals that bear gly-
cosylation in which analytical technologies will be crucial for
the regulatory process.
To date in 2017 and 2016, 11 and 14 new Biological License
Applications (BLAs) were granted respectively for in vivo ther-
apeutics from the FDA’s Centre for Drug Evaluation and
Research (CDER), see Table 1 [23]. The BLA licenses granted
in 2017 and 2016 for in vitro therapeutics are not discussed in
this section as they are outside the scope of this review. Of the
therapeutics approved in 2016 and 2017, 24 drugs (96%)
contain glycosylation, of which analytical techniques such as
ultra performance liquid chromatography (UPLC), mass spec-
trometry, or capillary electrophoresis (CE) remain vital tools for
validation and quality control, discussed in Sections 3–5.
Perhaps not surprisingly, only one BLA license granted by
the CDER in 2016 and 2017 does not contain glycosylation,
Atezolizumab which interestingly was designed for reduced Fc
effector function by eliminating glycosylation binding. Twenty
one (84%) of the therapies are based on mAbs, two therapies
(8%) as antibody drug conjugates (ADCs), one therapy (4%) as







MS (LC-MS, CE-MS, MALDI, IMS or
MS/MS with CID, ETD, IRMPD)

















Figure 3. Schematic for general analytical strategies for therapeutic glycoprotein characterization. A) Intact therapeutic glycoprotein characterization can be
conducted using mass spectrometry (MS) techniques such as direct infusion, liquid chromatography-mass spectrometry (LC-MS), tandem mass spectrometry (MS-
MS), matrix assisted laser desorption ionization (MALDI), capillary zone electrophoresis (CZE)-MS or ion mobility spectroscopy (IMS). Alternatively microarrays can be
employed using commercial or custom lectin/glycan binding protein GBP chips. Other general strategies employ chromatography techniques such as ion exchange
chromatography (IEX), reverse-phase (RP) chromatography or hydrophilic (HILIC) chromatography are these technologies are usually implemented orthogonally with
other techniques. B) Glycopeptide analysis is conducted with the initial treatment of therapeutic glycoprotein with Protease such as trypsin, Lys-C or Glu-C to release
glycopeptide fragments. This technique offers the advantage of site specific glycosylation information and glycopeptides are characterized using mass spectrometry
techniques such as LC-MS, CE-MS, MALDI, IMS or MS/MS using collision induced dissociation (CID), electron transfer dissociation (ETD) or infrared multiphoton
dissociation (IRMPD) for fragmentation. C) Released glycan analysis characterisation for therapeutic glycoproteins is performed using either enzymatic release for
N-glycans or chemical release for O-glycans. Analytical methodologies include MS techniques such as direct infusion, LC-MS, MS/MS, MALDI, IMS. Alternative
analytical methods include CE or (Ultra)-high performance liquid chromatography (HPLC/UPLC). The glycan structures are depicted with SNFG nomenclature [3].
(Permission for reprint of EPO structure granted by Dr. Mark Wormald, Oxford Glycobiology Institute).
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replacement therapy (4%), see Table 1. Of the mAb products
(84%) all are expressed as recombinant proteins, of which 18
are IgG1 derivatives and 3 are IgG4 variants. One notable
addition in this category is the combination of mAb with an
enzyme to speed up adsorption, reducing the drug adminis-
tration time for the patient (Rituxan Hycela). However, this
advance is unlikely to change the face of glycoanalytics unless
the enzyme affects the therapeutic glycosylation process. On
the other hand, the small shift toward ADCs and fusion pro-
teins in recent years will add another level of complexity for
glycoanalytical testing. For instance, drug antibody ratio (DAR)
of ADCs is important for therapeutic efficacy and pharmacoki-
netics, therefore control of DAR in synthesis processes requires
advances for fast real-time monitoring for quality control [24].
Many of these recently approved biotherapeutics are
expressed in CHO or Murine Myeloma cell lines (NS0 and
SP2/0). Protein production in these mammalian expression
systems has the advantage that they contain ‘human-like’
mammalian type glycans for therapeutic use compared to
bacterial, plant, or insect expression systems. Depending on
the expression systems, different glycoforms are produced
and can alter the pharmacokinetics, efficiency, and target-
ing of the glycoprotein [25]. CHO cells are the most com-
monly employed expression system in the
biopharmaceutical industry and are desirable for many rea-
sons including the high yields (2–6 g/L) for antibody pro-
ducts. On the other hand, CHO cells contain both
immunogenic galactose-α1,3-galactose (α-Gal) epitopes
[26,27], contrary to the assumption that CHO lacks the
biosynthetic machinery [28,29], and NGNA glycans not indi-
genous to humans [30] and as such the need to identify,
characterize, and minimize these glycans is paramount. The
murine cell lines NS0 and Sp2/0 are also used for recombi-
nant mAb production despite expressing the two predomi-
nant immunogenic glycan epitopes for humans as observed
for CHO cells, α-Gal, and NGNA glycans [29]. Therefore,
careful consideration is needed with regards to their gly-
coanalytical technologies for characterization of the CQAs
Table 1. Summary of approved in vivo therapeutic biologics under Biologics License Applications (BLAs) for 2016 and 2017 (until 30 September 2017) from FDA’s
Centre for Drug Evaluation and Research (CDER). Approvals by the Center for Biologics Evaluation and Research (CBER) are not included in this table. Columns
include, BLA numbers, drug name provided as trademark name, the active ingredient, glycosylation status (glycans) as Y or N for yes or no, biosimilar status as B for




number) Active ingredient Glycosylation Biosimilar Description
2016 Zinplava (761046) Bezlotoxumab Y Recombinant human IgG1 for Clostridium difficile toxin B
binding
Lartruvo (761038) Olaratumab Y Recombinant human IgG1 for human PDGFR-α binding
Stelara (761044) Ustekinumab Y Recombinant human IgG1κ for IL-12 and
IL-23 binding
Zinbryta (761029) Daclizumab Y Recombinant humanized IgG1κ for CD25 binding
Tecentriq (761034) Atezolizumab N Recombinant Fc-engineered IgG1κ
for PD-L1 binding
Cinqair (761033) Reslizumab Y Recombinant humanized
IgG4κ for IL-5 binding
Taltz (125521) Ixekizumab Y Recombinant IgG4 for IL-17A binding
Anthim (125509) Obiltoxaximab Y Recombinant chimeric IgG1κ for Bacillus anthracis toxin
binding
Amjevita (761024) Adalimumab-atto Y B (Humira) Recombinant human IgG1 for TNF binding
Erelzi (761042) Etanercept-szzs Y B (Enbrel) Recombinant dimeric fusion protein with portion of the
human TNFR linked to a modified human IgG1 Fc
Inflectra (125544) Infliximab-dyyb Y B (Remicade) Recombinant chimeric IgG1κ for human TNFα binding
2017 Bavencio (761049) Avelumab Y Recombinant human IgG1λ for PD-L1 binding
Ocrevus (761053) Ocrelizumab Y Recombinant humanized IgG1 for CD20 binding
Dupixent (761055) Dupilumab Y Recombinant human IgG4 for IL-4Rα binding
Brineura (761052) Cerliponase alfa Y Recombinant human rhTPP1, a lysosomal exopeptidase for
cleavage of N-terminal tripeptides
Imfinzi (761069) Durvalumab Y Recombinant human IgG1κ for PD-L1 binding
Tremfya (761061) Guselkumab Y Recombinant human IgG1λ for IL-23 blocking
Besponsa (761040) Inotuzumab
ozogamicin
Y Antibody drug conjugate with recombinant humanized
IgG4κ for CD22 binding, N-acetyl-gamma-calicheamicin
for cytotoxicity






Y A combination of rituximab and hyaluronidase human.
Rituximab is a recombinant chimeric murine/human
IgG1κ against the CD20 antigen. Recombinant human
hyaluronidase is an endoglycosidase used to increase the
dispersion and absorption of coadministered drugs
Kevzara (761037) Sarilumab Y Recombinant human IgG1 for IL-6 binding
Mylotarg (761060) Gemtuzumab
ozogamicin
Y Antibody-drug conjugate with recombinant humanized
IgG4κ for CD33 binding that is covalently linked to the
cytotoxic agent N-acetyl gamma calicheamicin
Benlysta (761043) Belimumab Y Recombinant human IgG1λ specific for soluble human B
327 lymphocyte stimulator protein
Cyltezo (761058) Adalimumab-adbm Y B (Humira) Recombinant human IgG1g for human TNF binding
Mvasi (761028) Bevacizumab-awwb Y B (Avastin) Recombinant humanized l IgG1 for VEGF binding
Renflexis (761054) Infliximab-abda Y B (Remicade) Recombinant chimeric IgG1κ for human TNFα binding
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with a strong focus on characterization of known antigenic
or immunogenic glycan epitopes.
Since approval of the first biosimilar in 2006 in Europe, there
is an increasing trend toward biosimilar production in an effort
to lower patient costs, especially in China and India, with both
countries expected to grow their biopharmaceutical industries
at the fastest compound annual growth rate of 30% and 29%
from 2013 to 2018 [31]. Detecting differences in glycosylation
between innovator drugs and biosimilars can be crucially
important to ensure the safety and efficacy of these emerging
drugs and the criteria is met by fulfilling the requirements of the
International Council for Harmonization’s (ICH’s) Q6B. Crucially,
the presence/absence of even one sugar residue can alter the
biologic activity of the agent [32]. Biosimilar approvals by FDA
in 2016 include Inflectra (Infliximab), Erelzi (Etanercept), and
Amjevita (Adalimumab), see Table 1 [23,33]. More recently in
2017 to date three biosimilars have also been approved by the
CDER including Cyltezo (Adalimumab), Mvasi (Bevacizumab),
and Renflexis (Infliximab). The comparison of the glycan profiles
of the biosimilar compared to the innovator drug is one of the
regulatory requirements, whereby the biosimilars are required
to be similar in structure to their biologic reference product but
are neither expected nor required to contain identical active
substances [34,35]. Taking the changing climate for modern
biopharmaceuticals into account glycoanalytical advances are
discussed in Sections 3–5.
3. Released N- and O-glycan analysis of therapeutic
glycoproteins
Glycosylation analysis of therapeutic proteins on the level of
released N-, or O-glycans gives a snapshot of glycan levels from
the pool of glycoprotein molecules. Profiling of N- and O-linked
glycans is an extremely important part of the quality control
strategy for ensuring lot and batch consistency for therapeutic
glycoproteins. Glycoprofiles may vary greatly depending on the
source of the therapeutic glycoprotein and certain glycan struc-
tures may cause anything from decreased serum half-life of a
compound to an extreme immune response [36,37]. For this
reason, WHO guidelines on therapeutic proteins and the
International Conference on Harmonization (ICH) Q6B mandate
state that posttranslational modifications such as glycosylation
should be identified and accurately characterized [38,39].
Glycosylation is also sensitive to alterations in the host cells
environment. Because of this, regular glycoprofiling is necessary
to ensure batch to batch consistency. Finally because of the
phenomena known as the ‘patent cliff’, there are a large number
of biosimilars entering the market. Both the European Medicines
Agency and the FDA require a detailed comparison of the sugar
structures through glycan profiling as part of the process in
confirming biosimilarity [39].
Released glycan analysis is very convenient for fast screen-
ing of therapeutic glycoproteins and QC assays. However, on
the other hand, it does not provide information relating to
glycosylation on each potential glycosylation site of a thera-
peutic glycoprotein. Released N- or O-glycoprofiling is based
on several major steps – purification of therapeutic glycopro-
tein from cell culture, release of glycans from purified
glycoprotein, chemical modification of released glycans for
the subsequent detection (usually with fluorescent detection),
clean-up procedure to remove excess reagents, and finally
detection of individual glycan species usually after chromato-
graphic or gel electrophoresis separation.
3.1. Purification of therapeutic glycoproteins
Protein purification contributes to a large portion of the expense
accrued in therapeutic protein production [40]. For this reason, the
design of a simple, cost-effective, protein isolation, and purifica-
tion process is key to developing a production strategy. Currently,
the three main methods for therapeutic glycoprotein purification
are affinity chromatography, ion exchange chromatography, and
fusion tags [41–43]. Affinity chromatography is most commonly
exploited in the case of therapeutic glycoprotein purification of a
single protein (e.g. a mAb). The technique affords separation of
biomolecules based on antibody-antigen/enzyme-substrate/
receptor-ligand binding and is generally a useful method for
targeting a single protein. Protein A is a good example of this
and is commonly employed in the biopharmaceutical industry
[44,45]. Protein A is found in the cell wall of the bacteria
Staphylococcus aureus and was found to strongly bind IgG anti-
bodies which are exploited for the capture of therapeutic mAbs.
However, the production of antibody purification systems can be
expensive so other intrinsic physicochemical properties of the
protein can be exploited such as the net charge of the glycopro-
tein through ion exchange chromatography. This method is
employed for the purification of recombinant human erythropoie-
tin (rhEPO) [46]. As there may be other proteins with a similar
charge in the media, ion exchange chromatography is usually
performed in combination with other separation techniques
such as HPLC and size exclusion chromatography. Again, these
additional steps add time and cost to the purification process.
Some proteins do not have any unique characteristics, for this
reason an affinity tag, such as glutathione-S-transferase or a histi-
dine tag (HisTag) can be added as a DNA sequence to the gene of
interest [47]. The gene product is now known as a recombinant
fusion protein. Additional tags which confer other desirable prop-
erties to a recombinant glycoprotein, such as increased solubility,
can also be added [40]. While the tags give great convenience in
the purification step, they may also be immunogenic once they
come into contact with the recipient’s immune system. Therefore,
the tag must be removed, usually with an endoprotease [47] and
depending on the design of the fusion protein the complete
removal of the tag is not always possible. This must be taken
into consideration when designing the purification method.
The high costs associated with purification of expressed pro-
teins in downstream processing is recognized as a major chal-
lenge for biopharmaceutical industry [48] and has encouraged
creativity in the field to investigate cost-effective solutions.
Improvements including alternatives to Protein A chromatogra-
phy [49], investigations into Protein A fouling [50] and incorpora-
tion of filtrationmethods [45] prior to Protein A chromatography
have all been explored in this context. It is clear, however, that
more efforts are needed for their mainstream application in the
biopharmaceutical industry.
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3.2. Methods for N-glycan release from therapeutic
glycoproteins
Analysis on the level of released glycans allows screening of
therapeutic glycoproteins for any variations in glycan struc-
ture, which can alter efficacy, half-life, or immunogenicity of
the therapeutic. Glycoproteins from different batches have to
have consistent released glycan profiles in order to meet
regulatory requirements or pass quality control. Generally,
there are two approaches for N-glycan release – chemical
deglycosylation (hydrazinolysis) and enzymatic reaction.
Hydrazinolysis is based on glycans release from glycopro-
tein using anhydrous hydrazine [19,51] and it requires clean
initial sample and several steps to minimize potential side
reactions. In addition to being more labor intensive, efficiency
of deglycosylation is usually lower and loss of glycans through
degradation in the procedure are higher compared to enzy-
matic deglycosylation, making it less suitable for biopharma-
ceutical use. On the other hand, glycosidases such as
N-glycosidase F (PNGase F) are very selective and specific,
and can be added directly to a denatured glycoprotein solu-
tion, that is, for recombinant erythropoietin biotherapeutics
[52]. Alternatively, the glycosidases can be employed in the
form of immobilized enzyme reactors. Many examples in the
literature [53–55] describe the release of N-glycans from gly-
coprotein standards such as IgG and fetuin using this metho-
dology and it can be harnessed in future applications for
method development of biopharmaceuticals to minimize asso-
ciated enzyme costs. N-glycan release is performed overnight,
in a few hours or even a few minutes depending on the
conditions and experimental setup for the recombinant glyco-
protein [56] and novel approaches such as microwave-assisted
or pressure cycling technology [57,58] can also be applied to
biopharmaceutical glycoanalytical platforms in the future.
PNGase F is most commonly used for profiling of total
N-glycans in biopharmaceuticals, except if they have α1,3
core-fucose residues, that is, if a therapeutic glycoprotein has
been expressed in insect or plant cells. Glycans containing
α1,3 linked fucose on the reducing-terminal GlcNAc on the
chitobiose core may instead be released using N-glycosidase A
(PNGase A; also known as glycoamidase A, see Figure 2)
[19,59], while endoglycosidase H (Endo H) is very convenient
for specific analysis of high-mannose glycans [60], useful for
characterization at the development stage for biotherapeutics
such as yeast or CHO produced therapeutic glycoproteins.
In the recent few years, several customized enzymes have
been developed for characterization of IgG antibodies by the
company Genovis and are very useful for N-glycan character-
ization of antibody-based therapeutics. For example, IdeS (com-
mercially known as FabRICATOR by Genovis, and also available
from Promega) specifically digests human IgG below the hinge
region and results in an F(abʹ)2 fragment and two Fc fragments,
therefore enabling characterization of N-glycans from both Fab
and Fc fragments after their separation [61–63]. Another appli-
cation of IdeS is separate characterization of glycans from Fc
part and fusion part of Fc fusion proteins (e.g. abatacept) that
have noncanonical hinge region [64]. Similarly, IdeZ protease
has the same specificity as IdeS, but with improved activity
toward mouse IgG2a and IgG3 subclasses, and has also been
used for characterization of Fc fusion protein (human cell line-
derived chimeric human Coagulation Factor VIII-Fc) [65].
Moreover, IgGZERO (EndoS) specifically cleaves after the first
GlcNAc residue in the Fc-region of native IgG, while
GingisKHAN digests only human IgG1 between K223 and T224
producing a homogenous pool of Fab and Fc fragments [66].
Although, these enzymes are still a higher price, the advantage
over widely used PNGase F is the possibility of targeted
N-glycan analysis, which is especially useful since different
regions/parts of Fc fusion proteins can have distinct glycosyla-
tion profiles and functions. This will find application in devel-
opment programs of therapeutic glycoproteins.
Purified therapeutic glycoproteins are generally denatured
and disulfide bonds reduced and alkylated prior to enzymatic
glycan release to minimize steric hindrance and make glycans
more accessible to an enzyme. For example, erythropoietin is
known to be resistant to PNGase F digestion without prior
denaturation [52]. However, improved recombinant glycosi-
dases are being developed that allow deglycosylation of
native glycoproteins, for example, IgGZERO (EndoS) and
GlycINATOR (EndoS2) from Genovis. Another trend is develop-
ment of rapid recombinant versions of PNGase F (for example
Rapid PNGase F by New England Biolabs), which deglycosylate
the glycoprotein substrate in only few minutes, therefore sig-
nificantly speeding up the analysis of therapeutic glycopro-
teins during QC, as well as enabling fast screening of a
therapeutic glycoprotein during the production process.
Exoglycosidase digestions are often used orthogonally with
N-glycan release strategies for characterization of therapeutics
at developmental stages, their relative high costs hinder their
routine use in QC assays. Glycoprotein digestion with neura-
minidase and subsequent UPLC or MS analysis could provide
information about presence and amount of sialic acids [64,65],
and other exoglycosidase digestions are used for characteriza-
tion of other glycan moieties [67,68]. Additionally, level of
sialic acids (Neu5Ac, Neu5Gc, and O-acetylated sialic acids)
could be determined by mild hydrolysis and subsequent label-
ing with 1,2-diamino-4,5-methylenedioxybenzene using a kit
developed by Ludger Ltd, which has recently been used in
analysis of three epoetin alpha products [69].
3.3. Methods for O-glycan release from therapeutic
glycoproteins
Unlike N-glycans, O-glycan release is challenging due to lack of
universal enzymes to cleave the O-glycans from proteins. Thus
chemical treatments have been employed to release O-glycans
from biopharmaceuticals such as reductive β-elimination
methods in dimeric fusion protein Etanercept [70,71] and
recombinant erythropoietins [12,72] or hydrazinolysis, see
Figure 2 [73,74]. Reductive β-elimination is useful for releasing
O-glycans attached to serine or threonine amino acid residues.
The glycoprotein is treated with base (usually mild sodium
hydroxide) to release the peptide/protein fraction as a dehy-
droamino acid derivative and the glycan portion is converted
into an alditol by reduction (usually using sodium borohydride
solution) to ensure minimal conversion into undesired
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‘peeling’ products obtained by degradation of the glycans.
However the reductive β-elimination reaction is limited as it
does not cleave O-glycans on amino acid residues hydroxyly-
sine, hydroxyproline, tyrosine, or certain serine/threonine resi-
dues (whereby glycans are decorated on the carboxylic acids).
The conversion to the alditol also prevents the reductive
amination needed for the attachment of a fluorophore or
chromophore [75]. Matrix-assisted laser desorption/ioniza-
tion–time of flight (MALDI-TOF) mass spectrometry serves as
a suitable technique to characterize the O-glycans using this
method as the glycans can be permethylated to increase the
ionization potential of the glycans [76].
Hydrazinolysis serves as an alternative method for O-glycan
detection but can be an arduous method that involves pre-
purification of the glycoprotein, anhydrous hydrazine, elevated
temperatures, removal of excess hydrazine, and re-acetylation of
N-acetyl functionalities [73]. Commercial kits are available includ-
ing GlycoProfileTM β-Elimination Kit (Sigma Aldrich) and
GlycoReleaseTM Glycan Hydrazinolysis Kit (Prozyme) which may
be useful for preliminary structural studies for therapeutic glyco-
proteins. However the challenges associated with preparation of
released O-glycans using this method limits its use for therapeu-
tic glycoproteins in QC assays.
Combinations of enzymes for O-glycan characterization,
although currently limited, may also be useful for glycosylated
biopharmaceuticals, including the use of O-glycanase (available
from Prozyme) which cleaves unsubstituted Ser/Thr linked Gal-
GalNAc from proteins. The exoglycosidase can be used in con-
junction with other enzymes/cocktails of enzymes such as prO-
LINK Extender™ Kit for Complex O-Linked Glycans (Prozyme) or
Protein Deglycosylation Kit (New England Biolabs) as well as
other commercial enzymes to decipher the O-glycan monosac-
charides. Some examples in the literature have highlighted enzy-
matic approaches to this end [77]; however, their main
application at present remains as useful tools to discover if
proteins are glycosylated in SDS page gels. Ongoing efforts in
the field to develop a universal O-glycanase, synonymous with
PNGase F for N-glycan characterization, if successful, may drama-
tically change the face of O-glycan characterization of therapeu-
tic glycoproteins in the future.
3.4. Fluorescent labeling of N-glycans and O-glycans
Glycans are not fluorophores and for their detection and quantifi-
cation by UPLC or CGE-LIF a labeling reaction with fluorescent tag
is necessary step in the workflow. However depending on the
release method for O-glycans, reductive amination, Michael addi-
tion, and hydrazide labelingmay not be suitable as they all require
the reducing end of the glycan, which is not present on O-glycans
released by reductive β-elimination. On the other hand, O-glycans
released by other methods may be fluorescently labeled. Several
fluorescent labels have been described for glycan labeling for
glycoproteins: 2-aminopyridine (PA) [78], 2-aminobenzoic acid (2-
AA) [79,80], 2-aminobenzamide (2-AB) [56,81], procainamide (4-
amino-N-(2-diethylaminoethyl) benzamide) [69,82] and more
recently aminoquinoline carbamate (AQC) [44] and RapiFluor-MS
(Waters) for the UPLC and MS techniques. For CGE-LIF, 8-amino-
pyrene-1,3,6-trisulfonate (APTS) and 2-amino-1-naphthalenesulfo-
nic acid (2-ANSA) can be used. However, routine use of some of
these reagents in the biopharmaceutical industry is limited due to
strict requirements for QC assays (i.e. reagents must be purchased
from reputable commercial sources). Traditionally commercial kits
such as LudgerTag 2-AB Labeling Kit (Ludger Ltd), 2-AB Labeling
Kit (QA-Bio), GlycoWorks 2-AB Labeling Reagent Kit (Waters),
Glycoprofile 2-AB Labeling Kit (Sigma-Aldrich), and GlykoPrep Kit
(Prozyme) are employed for 2-AB labeling, LudgerTag 2-AA
Labeling Kit (Ludger Ltd) and Glycoprofile 2-AA Labeling Kit
(Sigma-Aldrich) for 2-AA labeling or the most recently released
fast release kits such as GlycoWorks RapiFluor-MS N-glycan kit
(Waters) or Fast Glycan Labeling and Analysis Kit (SCIEX) can be
employed.
Geyer and Geyer have reported PA as one of the most com-
monly used label for the chromatographic glycan analysis [19].
However, since commercially available PA is not sufficiently pure
for this application, it has a limited use due to the necessary
additional step of recrystallization. 2-AA label is negatively
charged and due to this property widely used for labeled glycans
detection by techniques where separation and detection are
based on charge, for example, in CGE [83,84], positive-mode
MALDI-TOF-MS [79,85], and in negative-mode MALDI-TOF-MS
[86,87], allowing the detection of both neutral and sialylated
glycans in the same experiment. For example, 2-AA labeling
has been employed for comparison of a biosimilar to an innova-
tor biologic [88]. 2-AB is a neutral nonselective label that allows
accurate quantitative measurement of relative amounts of indi-
vidual glycans, both neutral and charged ones. It is compatible
with most chromatographic and mass spectrometric methods
used for glycan separation and analysis, and is mostly used for
glycan profiling by LC. On the other hand, however, 2-AB has a
poor ionization efficiency when glycan structures are analyzed
by ESI–MS [89]. Comparison of 2-AA and 2-AB showed that 2-AA
labeled glycans have higher intensities than 2-AB labeled glycans
when analyzed by RP-LC-MS analysis [90] or chromatographic
analysis [91]. With a shift toward the more commonplace use of
mass spectrometry in biopharmaceutical characterization 2-AA
labeling may be employed more frequently in the future.
The trend in the last few years is to develop labeling
reagents that allow efficient and sensitive detection, identifi-
cation, and quantification of labeled glycans both by chroma-
tographic and MS techniques in the scientific community.
Procainamide ((4-amino-N-(2-diethylaminoethyl) benzamide)
is an aromatic amine tag that allows glycan profiling and
identification both by UPLC-FLR and ESI-QTOF-MS [82], since
it provides efficient ionization due to the amine moiety.
Procainamide labeling allows the glycan analysis on multiple
levels using the same sample, which significantly reduces the
amount of initial sample that is needed for the glycoprotein
characterization and time needed for sample preparation.
Comparison of 2-AB and procainamide labeled glycans
showed higher fluorescent intensities of glycans labeled with
procainamide than with 2-AB, allowing more sensitive quanti-
fication of less abundant glycans [92]. In addition to that,
procainamide labeled glycans have excellent chromatographic
peak resolution when analyzed by UPLC-FLR and up to 10–50
fold more efficient ionization than 2-AB labeled glycans when
analyzed by ESI–MS [92]. Although it still has not been routi-
nely used for glycan analysis in biopharmaceuticals, due to the
number of advantages and commercial availability of
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procainamide kits (LudgerTag PROC glycan labeling kit,
Ludger Ltd, and InstantPC, Prozyme), this may change in the
future.
Another labeling reagent that allows high sensitivity detec-
tion by both fluorescence and MS (positive ion mode ESI-MS)
is RapiFluor-MS (Waters Corporation) and is suitable for ther-
apeutic glycoprotein characterization. This label has an
N-hydroxysuccinimide carbamate reactive group, a quinoline
fluorophore, and a basic tertiary amine [93]. Additional
advancement is the possibility of labeling reaction at room
temperature within only few minutes, compared to the tradi-
tional labeling reagents which require sample incubation at
65°C for 2–3 h [44,93]. Two other currently available ‘instant
labeling’ solutions in addition to RapiFluor-MS are InstantAB
from Prozyme and 6-aminoquinoyl-N-hydroxysuccinimidyl car-
bamate (AQC) commercially available by Synchem and Waters
Corporation, but can also be synthesized in-house [44,93,94].
AQC has also been shown to enhance the ionization yield for
MALDI-MS analysis [95]. Although some of the commercial
variants of these labeling reagents are not the best solution
for high-throughput glycomics at present due to the high cost
per sample, they can definitely find their place in the work-
flows for characterization of therapeutic glycoproteins where
number of samples is significantly lower, and time for the
analysis is of the essence, especially during the production
batch quality control.
Glycans released from the therapeutic glycoproteins which
will be separated and analyzed by CGE are most commonly
labeledwith triply charged APTS, which also allows electrophore-
tic separation of neutral glycans [96]. The labeling reaction also
contains reductants – sodium cyanoborohydride [55,58] or non-
toxic 2-picoline borane [97], and acetic or citric acid. APTS glycan
labeling with acetic acid usually takes 2 h, which is a trade-off
between loss of sialic acids and labeling efficiency [98]. On the
other hand, labelingwith citric acid for 50min at 50°C requires 10
times lower consumption of APTS with almost no loss of sialic
acids, compared to the incubation at 37°C overnight with acetic
acid [99]. An alternative to costly APTS is singly charged 2-amino-
1-naphthalenesulfonic acid (2-ANSA), which results in less effi-
cient glycan separation in CGE. However, 2-ANSA labeled glycans
are more efficiently ionized in CE-MS [96].
Native, unlabeled glycans can also be analyzed by various
techniques, for example, using MALDI-MS in negative reflec-
tron mode or nano-LC/Q-TOF MS system as was demonstrated
in a study of recombinant erythropoietin [52].
3.5. Labeled N- and O-glycans clean-up
Purification of fluorescently labeled glycans to remove protein
or excess reagents before the glycans analysis by method of
choice is an essential step in the glycan characterization work-
flow. Although paper chromatography [100,101], precipitation
[102] and gel-filtration [56,103] have been used for clean-up of
labeled glycans, the most commonly used for biologics are
different variations of solid-phase extraction (SPE)
[52,80,104,105], for example, anion-exchange, porous graphi-
tized carbon (PGC), reverse phase (RP), and hydrophilic chro-
matography (HILIC). They are usually supplied as part of the
glycan release kits.
Technological trends are to increase the throughput, mini-
mize the sample preparation time, and automate as more steps
as possible in the sample clean up. In the last decade, workflows
have become significantly faster and less labor intensive – from
deglycosylation of proteins in SDS-PAGE gels that took 4 days for
processing of 96 samples [106], to deglycosylation in solution
overnight and fast 1–2 h manual clean-up on the 96-well GH
Polypro (GHP) HILIC-SPE plate [104,107,108], or using Hypersep
Diol SPE cartridges [81,109]. Integration of the glycan prepara-
tion steps and robotization allowed very fast processing of 96 or
384 samples [44,110] in less than a day. Another reported
method for N-glycan purification on a robotized platform using
a PhyTip column packed with polyamide DPA-6S resin allowed
the clean-up of 96 samples in 23 min [111]. Automated work-
flows reduce the hands-on time as well as costs, and exhibit
good robustness and reproducibility. Although this has not yet
reached the level of a trained analyst, automation in glycoanaly-
tical technologies will improve over time and can be especially
useful for routine QC assays for biopharmaceutical industry.
Liquid handling stations from Hamilton or Tecan are suitable
choices for this automation.
Alternative purification strategies like magnetic beads have
also recently been used – glycans are reversibly captured on
the surface of carboxyl-coated microparticles and excess of
reagents and protein part of a glycoprotein are washed away
from the reaction mixture, this technology is employed in the
Fast Glycan Labeling and Analysis Kit (SCIEX) designed for
biopharmaceuticals [98]. This magnetic bead workflow has
been recently automated and applied for N-glycosylation ana-
lysis of therapeutic antibodies [55].
3.6. Detection of fluorescently labeled N- and O-glycans
and structure determination
Liquid chromatography separation of free labeled glycans and
their detection by fluorescence allow sensitive relative quantifi-
cation of glycans from a sample of therapeutic glycoprotein.
Separation mechanism is based on hydrophilic interactions and
there is a correlation between retention time and glycan size and
charge. By running a fluorescently labeled dextran standard
(glucose ladder) and assigning the glucose units (GU) to indivi-
dual glycan peaks, possible glycan structures can be assign to the
peaks with specific GU value using GlycoBase and autoGU data-
bases [112,113]. Commercial softwares such as Unifi and
MassLynx (Waters Corporation) software can also be applied for
use in discovery, development, and quality control.
Similar principles can be applied for the glycan detection and
identification by CGE, but withmaltodextrin as a standard ladder,
used routinely for therapeutic glycoproteins in lot releasing QC
and a tool allowing accurate quantitation [114]. Unidentified
oligosaccharides peaks are then assigned GUCGE units (glucose
units for CGE) by correlating the retention time and length of the
sugar oligomer and annotated by comparison of GUCGE values to
specific glycan structures in a database. The major disadvantage
of CGE method was the lack of standards and very scarce data-
base which could be used for glycan peak annotation.
Fortunately, this has been changing and recently a free database
with APTS labeled glycans has been developed and is being
expanded for use by glycobiologists and the biopharmaceutical
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industry [115]. Additionally, while chromatographicmethods can
easily be coupled with MS for identification of glycan peaks,
coupling of CGE and MS is very challenging due to several
reasons: gel and buffers used in CGE for glycan separation are
not compatible with MS analysis, modification of CGE system in a
way that would allow online MS analysis of eluting glycan peaks
significantly lowers CGE glycan separation resolution, fluorescent
label has to be compatible with both CGE and MS [116,117].
However, a lot of promising work has been done recently to
facilitate glycan characterization by connecting CGE separation
with MS detection and may be useful for future biologic char-
acterization methods [99,118,119].
Free glycans can also be analyzed by LC-MS using PGC col-
umn to separate glycans which are then detected by LC-MS. This
PGC-LC-ESI-MS system can be used for glycan isomers separation
and detection of N- and O-glycans both from individual glyco-
proteins and from complex mixtures [12,52]. Sialylated glycan
analysis by MS is usually less quantitative [120] due to the
sensitivity of sialic acids to temperature, pH, and ionization con-
ditions, although this may not be a major challenge for many
commercial glycoproteins such as mAbs as they do not usually
contain a high degree of sialic acids. On the other hand, it could
be problematic in characterization of specific highly sialylated
therapeutic glycoproteins. Additionally, sialylated glycans easily
form salt adducts resulting in multiple signals in the MS spec-
trum, while carboxyl group due to its negative charge decreases
the sialylated glycans signal in MALDI-TOF-MS positive ionization
mode. A typical approach is to introduce derivatization step to
make sialylated glycans more stable, analysis more sensitive and
quantification more robust. Although permethylation [121,122]
is most commonly mentioned, the number of transferred methyl
groups can vary making the interpretation and analysis more
complex. Other carboxylic acid-specific derivatization strategies
like methyl esterification [123] and methyl amidation [124]
require clean initial glycan sample and harsh derivatization con-
ditions, but also allow differentiation of glycans with α2,6 or α2,3
linked sialic acids. Another similar approach that enables differ-
entiation of α2,6 or α2,3 linked sialic acids is ethyl esterification
which uses 1-hydroxybenzotriazole monohydrate and 1-ethyl-3-
(3-(dimethylamino)propyl)carbodiimide hydrochloride in etha-
nol to almost completely modify only sialylated glycans [125].
After esterification, glycans are typically cleaned-up using HILIC-
SPE on cotton tips, sepharose, or hydrophilic GHP filter [125,126]
to remove the excess of reagents before the analysis. Since only
α2,6 linked sialic acid effects the anti-inflammatory activity of IgG
antibody [127], differentiation of α2,6 from α2,3 sialic acid isomer
is of utmost importance in the production of therapeutic anti-
bodies. This derivatization workflow has been automated using
liquid-handling robot system that can process 384 samples for
the subsequent MALDI-TOF-MS analysis of free N-glycans in only
7 h [126].
4. Glycopeptide analysis of therapeutic
glycoproteins
Therapeutic glycoprotein analysis on the level of glycopeptides
enables site-specific glycosylation analysis, which is a more
detailed level of characterization than analysis of released gly-
cans, see Figure 3. It also provides useful structural information
on the therapeutic glycoproteins heterogeneity and allows struc-
tural characterization of N- and O-glycopeptides. Therefore, the
technique is commonly used in the biopharmaceutical industry
during the characterization of the glycoprotein of interest or
during drug discovery and recombinant proteins erythropoietin,
follicle-stimulating hormone have been characterized using this
approach [18,128]. However, it is not usually employed in QC
assays as this approach is often more challenging since it
requires high-resolution sensitive MS techniques and due to
the high costs compared to UPLC/CE techniques used in released
N- and O-glycan characterization. The workflow involves the
digestion of the therapeutic glycoprotein with proteases such
as trypsin, Lys-C, or Glu-C to give glycopeptide fragments, gly-
copeptide enrichment, and mass spectrometry techniques such
as LC-MS, MALDI, ion mobility, and the increasingly popular MS/
MS, see Sections 4.1–4.3.
4.1. Digestion of therapeutic glycoproteins to
glycopeptides
The usual approach in glycopeptide analysis is a specific enzymatic
digestion of a glycoprotein with a protease, most commonly
trypsin, and the reaction is performed overnight at 37°C. Some
alternative faster protocols have been described include trypsini-
zation in a microreactor [129] or in a microwave oven [130–132]
whichmay be useful tools for future glycopeptide characterization
of therapeutics. In certain circumstances, other proteases are
employed either independently or as a cocktail with trypsin such
as in a study of recombinant erythropoietin [133]. In this case,
trypsin and Glu-C were used in combination. In another example,
chymotrypsin was the protease of choice for the recombinant
glycoprotein follicle stimulating hormone, which was found to
exhibit superior digestion to trypsin [134].
One challenge associated with the use of trypsin with glyco-
proteins compared to non-glycosylated proteins is that it can
result in missed cleavages that are near glycosylation sites due to
the steric hindrances from the glycan and produce glycopeptides
that are too large for the subsequentMS analysis. Thereforemore
and more alternative approaches to trypsin digestion for glyco-
peptide analysis have emerged to overcome this obstacle. For
example, the nonspecific proteases (e.g. pronase which contains
a mixture of exo- and endo-proteinases) are very useful in glyco-
peptide analysis because they result in short glycopeptides sui-
table for MS/MS approaches [135–138]. At present, they are
limited to pure proteins preparations only due to the increased
heterogeneity of the produced glycopeptides derived from the
same site but with different peptide lengths as well as the glycan
heterogeneity. This characteristic therefore only poses a minor
challenge for therapeutic glycoprotein analysis, with their high
degree of purity.
The other approach to evaluate glycan site-specific glycosy-
lation information is to treat the glycoprotein with PNGase F,
which converts the Asn residues on the protein to Asp and a
shift of one mass unit for each N-glycosylation site. Thus, when a
deglycosylated protein is further digested with a protease such
as trypsin, the peptides that are bound to the glycan moiety will
be 1 Da heavier than the expected theoretical mass and the
structures can then be characterized using MS [136].
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4.2. Glycopeptide enrichment
The relative poor ionization of glycopeptides (and glycoproteins)
compared to their non-glycosylated counterparts for MS techni-
ques poses a challenge for the characterization of therapeutic
glycoproteins. Additionally, non-glycosylated peptides from the
reaction mixture, as well as excess of reagents can further sup-
press the ionization of glycopeptides, therefore lowering the
sensitivity and in turn the relative quantification of glycopeptides
for therapeutic glycoprotein characterization. Enrichment and/or
purification of glycopeptides after digestion is commonly an
integral part of the glycopeptide analysis workflow to improve
sensitivity and enhance detection respectively for MS [139]. There
are number of different enrichment approaches for glycopeptide
analysis applicable for therapeutic glycoprotein characterization
described in the literature. Notably, reverse phase C18-SPE which
is based on the glycopeptide retention on the stationary phase
due to the peptide hydrophobicity [120], or HILIC-SPE [125,140]
or HILIC beads [129] which is based on the glycopeptide or
glycan partitioning into the water layer on the stationary phase
surface are gaining traction. Also, in recent years, more and more
workflows are based on glycopeptide binding to functionalized
beads [141] or magnetic particles [141,142] to integrate and
simplify the steps of glycopeptide preparation for the subse-
quent analysis. Additionally PGC, lectin, immunoaffinity, hydra-
zide, boronic acid, or click chemistry enrichment approaches
have also been described [18,128,135,138,139] for glycopeptide
enrichment. However, at present, HILIC enrichment is the most
promising technique for therapeutic glycoproteins as it displays
superior separation for glycopeptides and forms the basis for
various commercial kits. Commercially available glycopeptides
enrichment kits suitable for biopharmaceutical industry include
ProteoExtract® Glycopeptide Enrichment Kit (EMD Millipore) and
LudgerTag V-TAG glycopeptide labeling and enrichment kit
(Ludger Ltd).
4.3. Glycopeptide analysis
Glycopeptide characterization of therapeutic glycoproteins is
performed using MS techniques, with identification and struc-
tural characterization and quantification afforded using LC-MS,
CE-MS, MALDI, ion mobility spectroscopy (IMS), and increasingly
tandem mass spectrometry (MS/MS). For quantification, either
label-free quantificationmethods or quantificationmethodswith
stable isotope labeling or stable isotope-coded internal stan-
dards can be used. These MS techniques allows characterization
of N- and O-glycopeptides and are especially useful in the case
for O-glycopeptides, as the corresponding released O-glycan
analysis technologies are currently limited as described in
Section 3.3. Representative examples of glycopeptide analysis
of therapeutic glycoproteins employing LC-MS [143–145],
CE-MS [133], and MALDI [146] are provided and can be suitable
technologies for glycopeptide analysis of therapeutic glycopro-
teins. However, in recent years, there is a trend toward the
alternative use of IMS or MS/MS techniques for glycopeptide
analysis of therapeutic glycoproteins [128,139].
Simply detecting them/z values of the glycopeptide fragments
of glycoforms is typically not sufficient for high confidence analysis
of therapeutic glycoproteins. Instead fragmentation data using
MS/MS on the glycoforms should be provided with techniques
such as collision-induced dissociation (CID), electron transfer dis-
sociation (ETD), or infrared multiphoton dissociation or combina-
tions thereof, see Figure 3 [128,147,148]. All of these technologies
work on the principle that dissociation of the parent molecule/ion
into smaller fragments can be used to characterize the precursor
molecule/ion and each offer unique strengths and weakness for
glycan structural elucidation. No consensus in the field exists to
the preferential method for therapeutic glycoproteins. While CID
provide information related to the composition of glycan moiety
attached to a peptide backbone, ETD allows fragmentation of only
peptide backbones while keeping posttranslation modifications
intact, thus a combination of the techniques is seen as advanta-
geous for glycopeptide characterization, as demonstrated by
Mechref [149]. Higher-energy collisional dissociation (HCD), a CID
technique specific to the orbitrap mass spectrometer, is another
technique which has shown extremely high resolving power to
characterize recombinant proteins, that is, human IgG1 reference
material from NIST was characterized using a range of HCD colli-
sion energies [150].
The IMS approach for glycopeptide characterization has
gained traction due to its ability to resolve different isobaric
glycopeptides with identical m/z values but different compo-
sitional structures, linkages, or branching [151] such as those
containing different NANA linkages [152] and the technique is
often used in conjunction with MS/MS techniques. The princi-
ple of IMS relies on the separation of biomolecules based on
their collisional cross-sectional size through a buffer gas [153];
as such glycan branching, linkages, and structures can be
differentiated using the technique. High field asymmetric
wave ion mobility spectrometry, also known as differential
ion mobility was employed to separate isomeric O-linked gly-
copeptides from the glycoprotein mucin 5AC with identical
sequences but differing glycosylation sites [154]. Additionally,
traveling wave IMS-MS was used to characterize IgG1 mAb
glycosylation heterogeneity profile [155]. One possible short-
fall for its application for characterization of therapeutic gly-
coproteins is the limited availability of the softwares available
for IMS data interpretation [156] and improvements are
needed in the future.
Bioinformatic tools for the characterization of therapeutic gly-
coproteins lags far behind the more established omic technolo-
gies such as genomics and proteomics. Softwares and
bioinformatic tools for glycopeptide characterization of therapeu-
tic glycoproteins are often specialized toward the particular mass
spectrometry technique and are reviewed in the literature
[157,158]. Broadly speaking there are four classifications of tools
available for therapeutic glycoproteins: (1) those that facilitate
data input using (high resolution) MS data; (2) those that facilitate
data input using MS/MS data; (3) those that allow a combination
of MS and MS/MS data input; (4) those that allow IMS data input.
These can be further divided into freely available software, of
which there are many [156,159–162] and commercial softwares
such as SimGlycan, ProSightPC Software, SIEVE Software for
Differential Analysis (Thermo Scientific), MassHunter Software
(Agilent), Byonic Software (Protein Metrics), or BiopharmaLynx
(Waters Corporation).
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5. Intact glycoprotein analysis of therapeutic
glycoproteins
Intact glycoprotein analysis can be important for detection and
separation of heterogeneous glycoforms of an intact therapeutic
glycoprotein. Although lectin arrays and HPLC/UPLC methods can
be useful tools for intact glycoprotein analysis [18], the vast major-
ity of intact glycoprotein analysis is conducted usingmass spectro-
metry techniques, see Figure 3. Similarly to glycopeptide analysis,
enrichment techniques such as CE, HILIC, RP, ion exchange, PGC,
lectin, antibody are often employed for intact glycoprotein analy-
sis of therapeutics [163–167]. MS and MS/MS analysis can then
accurately assign different glycoforms of therapeutic glycopro-
teins [18]. As is the case for many IgG mAbs on the market, only
Fc glycosylation is present (two sites, see Figure 1) and intact
glycoprotein analysis identifies and characterizes ion pairs such
as G0F/G0F (FucGlcNAc2Man3GlcNAc2 is designated G0F), G0F/
G1F (FucGlcNAc2Man3GlcNAc2Gal is designated G1F), G1F/G1F,
and G1F/G2F (FucGlcNAc2Man3GlcNAc2Gal2 is designated G2F)
for your mAb, see Figure 3 for a representative chromatogram.
Analysis of intact monoclonal IgG antibodies have been reported
for MS techniques including MALDI [168], electrospray ionization
(ESI) source [169], capillary zone electrophoresis-electrospray-mass
spectrometry (CZE-ESI-MS) [170], and a combination of mass and
top down analyses [164]. MS/MS techniques have the power to
give a more comprehensive coverage and ionization techniques
such as ETD [171] and CID [164] have been employed in the
characterization of intact therapeutic glycoproteins. It should be
noted that many more examples of glycopeptide analysis of
therapeutic glycoproteins using MS and MS/MS techniques are
found in the literature compared to intact glycoprotein however.
Native or near native mass spectrometry using the ‘top-down’
MS technique is an important tool to characterize intact thera-
peutic glycoproteins at their pseudo physiological environment
and offers many attractive features to the biopharmaceutical
industry. The technique allows measurement of glycoproteins
in their folded conformation, but also allows dynamic and pro-
tein stability studies, as well as assessment of their structural
properties [172]. The principle relies on the direct infusion of
the biopharmaceutical after buffer exchange into the mass spec-
trometer and ionization is afforded with soft ionization techni-
ques such as ESI such as Nano-ESI with (quadrupole)-time-of-
flight (q)TOF analyzers [172–174]. In the future, the application of
native mass spectrometry for characterization of therapeutic
glycoproteins will increase with advances in MS because the
technology has the capability to identify folding, protein, and
glycan structural information as well as relative quantitation in a
single experiment. With similar promise for the future applica-
tions for therapeutic glycoproteins, IMS, which is finding wide-
spread use in glycopeptide analysis, is quite limited to date with
respect to its application in intact glycoprotein analysis, although
it has been used for structural elucidation of glycoforms for
glycoprotein IgG2 [175].
For data analysis of intact glycoproteins using MS or MS/MS
techniques, users can employ many of the software packages
described for glycopeptide analysis including the commercial
products SimGlycan, ProSightPC Software and SIEVE Software
for Differential Analysis (Thermo Scientific), Byonic software
(Protein Metrics), MassHunter (Agilent), and MassLynx,
BiopharmaLynx (Waters). For native mass spectrometry,
ProSightPC Software (Thermo Scientific), Byonics software
(Protein Metrics), and MassLynx (Waters) can be employed.
6. Conclusion
Glycoanalytical technologies are essential for characterization
of therapeutic glycoproteins for drug discovery, development,
and for QC lot and batch variations to ensure safety and
efficacy of the biotherapeutic. As discussed in this review,
glycosylation analysis can be undertaken implementing var-
ious analytical techniques such as LC, CE, and MS techniques
or combinations thereof. Recent advances in these technolo-
gies have been described with a focus on their (potential)
application in the biopharmaceutical industry accordingly
and are discussed in the context of their classifications as
released glycan analysis, glycopeptide analysis, and intact gly-
coprotein analysis. Relevant strengths and limitations of each
technology toward characterization of therapeutic glycopro-
teins are described and specific case studies are provided,
where possible. In this regard, there is no accepted ‘gold
standard’ standardized approach for therapeutic glycoprotein
characterization and instead the industry must use customized
methods for characterization of their therapeutic glycopro-
tein/s. This remains a challenging feat and much needed
efforts are required toward the formation of suitable guide-
lines to overcome some of these hurdles. Nevertheless, the
significant potential that novel glycoanalytical technologies
hold toward improving the detection of glycans in biothera-
peutics, for example, from potentially immunogenic sources
will lead to safer and more effective drugs in the future.
7. Expert commentary
Eight out of 10 best selling drugs in Europe are glycoproteins
[176] and there is a crucial need for advancement in under-
standing and characterization of glycosylated biotherapeutics.
The manufacture of glycoprotein biologics such as mAbs,
cytokines, or therapeutic replacement enzymes is more chal-
lenging than for traditional small molecule drugs. Minor altera-
tions in the production process can dramatically alter the
efficacy or immunogenicity of the drug product and posttran-
slation modifications such as glycosylation can often play a
dominant role. Consequently, strict requirements are neces-
sary for validation, lot release, and batch release of glycosy-
lated biotherapeutics to satisfy regulatory bodies. To this end,
many biopharmaceutical companies already have well-estab-
lished glycoanalytical platforms for their biotherapeutics char-
acterization. However, the balance between maintaining
established glycoanalytical tools and the development of
novel glycoanalytical technologies will need to be adjusted
to accommodate new advances in the field toward ultimately
producing safer and more efficacious biologics. This will
require participation from both industry, regulatory bodies
and governmental agencies whereby incentives are provided
to update current platforms to use state of the art glycoana-
lytical technologies, both for their established products and
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those that are emerging. For the novel glycoanalytical meth-
ods, the focus should be to develop fast, cheap, automated,
robust, and user friendly methods while maintaining the
requirements set out by the regulatory requirements.
A recent trend is the increasing emphasis on understanding
the nature of the glycans of the therapeutic glycoprotein.
Given that various cell lines, expression hosts and protocols
can result in different glycosylation patterns [25], measuring
and understanding glycosylation using analytical techniques is
crucial. With improvements such as increased sensitivity for
glycan detection and upgrades in the state of the art instru-
mentation, analytical techniques now allow lower levels of
detection of glycans than in the past. This proves particularly
important for the biopharmaceutical field toward the identifi-
cation and reduction of particular epitopes that may be immu-
nogenic, such as α-Gal or Neu5Gc; also known as NGNA.
Additionally, MS advances including native mass spectrometry
and IMS are particularly exciting and will provide additional
structural information of the therapeutic glycoproteins. As
summarized throughout this review, accumulated reports
clearly indicate strong evidence that emerging glycoanalytical
approaches will successfully contribute toward developing
safer and more efficacious biotherapeutics.
8. Five-year view
The use of glycoanalytical approaches with respect to biophar-
maceuticals will continue to expand during discovery, in the
clinics and in manufacturing phases of biopharmaceuticals
with continuous development of more sensitive instrumenta-
tion, methodology, and novel commercial applications. One
existing problem remains how to develop and expand new
technologies for the characterization of released O-glycans of
therapeutic glycoproteins. O-glycopeptide analysis on the
other hand is far more developed but is not suitable for
many QC assays. Unlike N-glycans, no global enzyme has
been found to date to successfully digest all O-glycan struc-
tures in glycoproteins and as such chemical methods are
currently employed. Persisting problems with undesirable
peeling products, the selectivity of these methods and a
need for chemical expertise hampers their analyses. A novel
O-glycan global enzyme would solve the problem. However, in
its absence, standardized, user friendly approaches and novel
technologies are needed to overcome some of these short-
comings in the future.
Ongoing efforts for automation and standardization of
typical glycoanalytical workflows for glycoprotein characteri-
zation enable high throughput analyses [81,110], and thus
drive the field of glycomics toward more clinical applications
and standardized approaches useful for the biopharmaceutical
industry, particularly for QC assays where robustness and
reproducibility will likely improve with increased automation.
Glycosylation Critical Quality Attribute criteria will tighten for
biopharmaceuticals as the technologies improve and a deeper
understanding of the biological effects is known. Moreover,
the glycomics toolbox will enlarge with the growing interest in
the field with advances in glycoengineering of biologics for
improved immune functions [25], improvements in intact gly-
coprotein analyses, and aggregation studies for glycan
heterogeneity and macroscale considerations [18]. There is
also a recent focus on personalized medicines, of which gly-
coanalytical technologies for their characterization will be
developed. To conclude, the recent and upcoming develop-
ments in the glycoanalytical technologies and their employ-
ment in the analysis of therapeutic glycoproteins are most
exciting for the future and will aid the pharmaceutical industry
to exploit the full potential of their biopharmaceuticals.
However, there is much room for improvement with regard
to standardization of glycoanalytical techniques and the
development of a glycoanalytical technique for glycomics
synonymous with CRISP-Cas for genomics that address all
the different aspects important for characterization of
biotherapeutics.
Key issues
● Glycosylation of a therapeutic glycoprotein is a Critical
Quality Attribute. At present, it is difficult to obtain a full
complement of structural information from one single tech-
nique. Therefore a combination of released glycan, glyco-
peptide and intact glycoprotein profiling is required to
structurally characterize the protein sequence, glycan moi-
eties and glycosylation sites of a therapeutic glycoprotein.
● Glycoanalytical techniques are often cumbersome, labor-
ious and manual and at present need expertise of a trained
analyst. Automation and robotization will increase through-
put and enhance robustness of glycoanalytical methods.
● Therapeutic glycoproteins are expressed in various expres-
sion systems such as CHO or murine myeloma cell lines and
the role of glycosylation can be complex. The association
between protein glycosylation and specific immune func-
tion can be poorly understood and can result in adverse
immune reactions. Additionally, many antibody drug con-
jugates and fusion proteins are being developed by bio-
pharmaceutical industry. There is a need for special
consideration and techniques to minimize any undesired
immune responses in humans and to extent current analy-
tical technologies to expand these new classes of
biotherapeutics.
● Improvements in sensitivity and resolution of glycoanalyti-
cal technologies is needed for detection of low abundant
glycoforms. Development and expansion of analytical tech-
nologies for released O-glycan characterization of therapeu-
tic glycoproteins for QC assays is especially needed also.
● Bioinformatic tools, software packages and data analysis in
the field of glycomics lags far behind proteomics or geno-
mics and development of commercial packages which
allow data input (and manipulation and visualization) from
released glycan, glycopeptide and glycoprotein experi-
ments using various source inputs for orthogonal charac-
terization of therapeutics is strongly needed.
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